Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC + CRS + durvalumab for biliary tract cancer with peritoneal metastases
ChiCTR2500115410Phase 4Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Dec 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of durvalumab in biliary cancer, cholangiocarcinoma (CCA), gallbladder cancer and 1 more, sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Overall survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancermyeloid/lymphoid neoplasm with eosinophilia and FLT3 rearrangement
Beyond the preview
Go deeper on ChiCTR2500115410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115410.